Why the study?
It was hypothesized that adding semaglutide to standard care would reduce major adverse cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease without diabetes.
Does semaglutide reduce the risk of major adverse cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease who do not have diabetes?
Does semaglutide reduce the risk of major adverse cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease who do not have diabetes?
This paper reviews the design and baseline characteristics of the SELECT trial, which evaluates the cardiovascular benefits of semaglutide in non-diabetic patients with obesity and established cardiovascular disease.
Answers are grounded in this paper and cite their sources.
SELECT design details enable future result interpretation; leaves open semaglutide's cardiovascular effects in non-diabetic obesity.
In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial, the SELECT Investigators tested the hypothesis that the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA), to standard care would reduce the risk of major adverse cardiovascular events (MACE) among patients with overweight or obesity and pre-existing cardiovascular disease (CVD) who did not have diabetes. SELECT was a company-funded, multicentre, double-blind, randomized, placebo-controlled, event-driven superiority trial. Patients were eligible if they were 45 years of age or older, had a body mass index (BMI) of 27 kg/m 2 or higher, and had established CVD [defined as previous myocardial infarction (MI), previous stroke, or symptomatic peripheral arterial disease]. Key exclusion criteria were a previous diagnosis of diabetes, a baseline glycated haemoglobin (HbA1c) level of 6.5% or higher, treatment with any glucose-lowering medication or GLP1-RA within the previous 90 days, New York Heart Association class IV heart failure (HF), or end-stage kidney disease or dialysis. Patients were randomly assigned in a 1:1 ratio, without stratification, to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg (to be escalated from a starting dose of 0.24 mg over 16 weeks) or placebo. Patients were treated for the underlying CVD according to evidence-based recommendations. If diabetes mellitus developed during the trial, the patient continued to take the assigned trial product, and the use of glucose-lowering medications was at the discretion of the Investigator, with the exception of open-label treatment with a GLP1-RA that was prohibited by the protocol. The primary efficacy endpoint was a composite of death from CV causes, non-fatal MI, or non-fatal stroke, assessed in a time-to-first-event analysis. Confirmatory secondary endpoints, tested in hierarchical order, were CV death, a composite HF endpoint (CV death or hospitalization or an urgent medical visit for HF), and death from any cause. The basic assumptions for the sample size calculation were a 2.2% annual rate of MACE in the placebo group and a 17% relative risk reduction in the semaglutide group. A minimum of 1225 primary endpoint events were required for 90% power to detect such a benefit. From October 2018 through March 2021, a total of 17 604 patients (mean [ SD] age, 62 9 years; 72% male) underwent randomization.
No takes yet. Share an insight, caveat, or question.
Liuzzo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: